Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig

On this week's episode of the Business of Biotech, David Craig, Cofounder, President, and CEO at Sarcomatrix, explains why the old biotech playbook breaks down in today’s funding environment and what it takes to build a lean virtual drug development company without institutional financing. Craig describes practical financing paths, hard truths about costs, and the tradeoffs that make a rare disease program investable through alternative fundraising strategies. He also shares what can and cannot be outsourced, and how regulatory sequencing shapes financial planning and timelines.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Get in touch with guest and topic suggestions: ben.comer@lifescienceconnect.com

Find Ben Comer on LinkedIn https://www.linkedin.com/in/bencomer/

Find the Business of Biotech wherever you get your podcasts.